View in EDS HTML Full Text PDF Full Text

Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine in Patients With Inflammatory Bowel Disease on Vedolizumab or Anti-Tumor Necrosis Factor Therapy.

Saved in:
Bibliographic Details
Title: Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine in Patients With Inflammatory Bowel Disease on Vedolizumab or Anti-Tumor Necrosis Factor Therapy.
Authors: Caldera F; Department of Medicine, Division of Gastroenterology and Hepatology, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, Wisconsin, USA., Mogallapalli H; Department of Medicine, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, Wisconsin, USA., Abusalim AR; Department of Medicine, Division of Hospital Medicine, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, Wisconsin, USA., Farraye FA; Inflammatory Bowel Disease Center, Department of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA., Hayney MS; School of Pharmacy, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, Wisconsin, USA.
Source: Clinical and translational gastroenterology [Clin Transl Gastroenterol] 2025 Nov 01; Vol. 16 (11), pp. e00924. Date of Electronic Publication: 2025 Nov 01.
Publication Type: Journal Article; Comparative Study
Journal Info: Publisher: Wolters Kluwer Health Country of Publication: United States NLM ID: 101532142 Publication Model: Electronic Cited Medium: Internet ISSN: 2155-384X (Electronic) Linking ISSN: 2155384X NLM ISO Abbreviation: Clin Transl Gastroenterol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40995992
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine in Patients With Inflammatory Bowel Disease on Vedolizumab or Anti-Tumor Necrosis Factor Therapy.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Caldera+F%22">Caldera F</searchLink>; Department of Medicine, Division of Gastroenterology and Hepatology, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, Wisconsin, USA.<br /><searchLink fieldCode="AU" term="%22Mogallapalli+H%22">Mogallapalli H</searchLink>; Department of Medicine, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, Wisconsin, USA.<br /><searchLink fieldCode="AU" term="%22Abusalim+AR%22">Abusalim AR</searchLink>; Department of Medicine, Division of Hospital Medicine, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, Wisconsin, USA.<br /><searchLink fieldCode="AU" term="%22Farraye+FA%22">Farraye FA</searchLink>; Inflammatory Bowel Disease Center, Department of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.<br /><searchLink fieldCode="AU" term="%22Hayney+MS%22">Hayney MS</searchLink>; School of Pharmacy, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, Wisconsin, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101532142%22">Clinical and translational gastroenterology</searchLink> [Clin Transl Gastroenterol] 2025 Nov 01; Vol. 16 (11), pp. e00924. <i>Date of Electronic Publication: </i>2025 Nov 01.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Comparative Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wolters+Kluwer+Health%22">Wolters Kluwer Health </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101532142 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2155-384X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222155384X%22">2155384X </searchLink><i>NLM ISO Abbreviation: </i>Clin Transl Gastroenterol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40995992
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.14309/ctg.0000000000000924
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e00924
    Titles:
      – TitleFull: Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine in Patients With Inflammatory Bowel Disease on Vedolizumab or Anti-Tumor Necrosis Factor Therapy.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Caldera F
      – PersonEntity:
          Name:
            NameFull: Mogallapalli H
      – PersonEntity:
          Name:
            NameFull: Abusalim AR
      – PersonEntity:
          Name:
            NameFull: Farraye FA
      – PersonEntity:
          Name:
            NameFull: Hayney MS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2025 Nov 01
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2155-384X
          Numbering:
            – Type: volume
              Value: 16
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: Clinical and translational gastroenterology
              Type: main
ResultId 1